Moleculin Biotech, Inc. announced promising results from their Phase 1B/2 trial of Annamycin for treating soft tissue sarcoma lung metastases, showing a robust clinical benefit rate of 59.4% among ...
Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...
The survival rate for people with lung cancer is improving, according to the new State of Lung Cancer report. The American Lung Association report says there have been important advances in early ...
Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and Progression Free Survival (“PFS”) Clinical Benefit Rate (“CBR”) was 59.4% (n=32), comprised of ...
Camrelizumab plus chemotherapy doubled the five-year survival rate in advanced squamous lung cancer to 27.8%, reducing mortality risk by 43%. The CameL-sq trial demonstrated camrelizumab's efficacy as ...
The survival rate among those with lung cancer has improved by more than a quarter in the last five years, according to a new report. Four years ago, the United States Preventive Services Task Force ...
Verywell Health on MSN
Metastatic lung cancer symptoms and treatment
Medically reviewed by Doru Paul, MD Metastatic lung cancer is cancer that has spread (metastasized) from the lungs to other ...
Fragmented care - receiving medical treatment at more than one facility - has been associated with both positive and negative outcomes for cancer patients depending on a number of factors such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback